Summus Works, Inc. Acquires Assets and Operations of BioPharmetics, Inc.
SUN VALLEY, Calif., Aug 13, 2007 (*********wire via COMTEX News Network) -- Summus Works, Inc. (Pink Sheets:SMMW) announced the Company has successfully acquired substantially all the assets and business operations of BioPharmetics, Inc. (Pink Sheets:BPMT).
Three subsidiary divisions of BioPharmetics, Inc. provide quality durable medical equipment, diabetic supplies, and health, beauty, and anti-aging products to customer in the U.S., Canada, and over 23 countries throughout the world. The largest -- the pharmaceutical division -- distributes medical equipment and diabetes supplies, and dispenses physician-prescribed medications through its pharmacy partners. Additionally, the division works closely with a dealer network of health care companies and managed care facilities to provide superior pricing and customer support for Medicare, Medi-Cal, Medicaid and private insurance reimbursement programs.
The Biotechnology division is available for clients wanting to manufacture and test potential prescription medications and assist to facilitate the necessary FDA clinical trials in order to gain approval.
The cosmetic division manages the distribution of the TOMA line of cosmetics as well as private label manufacturing for companies seeking to enter the market place with their own formulations and ideas. BioPharmetics, Inc. was founded in 2005 and is headquartered in Sun Valley, CA.
The acquisition remains subject to the execution of definitive agreements and approvals. The closing date and further information will be released publicly.
This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
posted
Second PR Today, states all, and this one is CRYSTAL CLEAR....no questions to be asked....
Summus Works, Inc. Closes Acquisition of BioPharmetics, Inc.
SUN VALLEY, Calif., Aug 13, 2007 (*********wire via COMTEX News Network) -- Summus Works, Inc. (Pink Sheets:SMMW) announced the Company has closed its acquisition of substantially all the assets and business operations of BioPharmetics, Inc. (Pinksheets:BPMT). All definitive agreements pertinent to the acquisition have been executed and approved by the company.
Three subsidiary divisions of BioPharmetics, Inc. provide quality durable medical equipment, diabetic supplies, and health, beauty, and anti-aging products to customers in the U.S., Canada, and over 23 countries throughout the world. The largest -- the pharmaceutical division -- distributes medical equipment and diabetes supplies, and dispenses physician-prescribed medications through its pharmacy partners. Additionally, the division works closely with a dealer network of health care companies and managed care facilities to provide superior pricing and customer support for Medicare, Medi-Cal, Medicaid and private insurance reimbursement programs.
The Biotechnology division is available for clients wanting to manufacture and test potential prescription medications and assist to facilitate the necessary FDA clinical trials in order to gain approval.
The cosmetic division manages the distribution of the TOMA line of cosmetics as well as private label manufacturing for companies seeking to enter the market place with their own formulations and ideas. BioPharmetics, Inc. was founded in 2005 and is headquartered in Sun Valley, CA.
This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
posted
If SMMW CEO has a good plan, he can easily turn things aroung in BPMT and make SMMW a multi-million dollar company. Now that they have a good product and with the buyback underway, this could run big time very soon.
IP: Logged |
posted
So I guess we aren't selling ski's anymore? I was confident Dan knew how to ski. What does he know about biotechnology?
I've had an open order to sell my 40,000,000 for a month and nothing ... Think I should hold out to see if Dan figured out how to run a pharmecutical company?
IP: Logged |
posted
What is "substantially all"? Is that a new way to say some? A little less than most? More than a lot, but less than the kit and kaboodle?
IP: Logged |
As can be seen in the chart, zillions of shares are bought at .00001 or .00002 and flipped at .00009 or so almost continually. The only ones with that loophole are the MM's and they're not letting this out of the basement. This has been going on for many many moons and I don't see this POS ever seeing the light of day. Just another dead triple zero for us. I suspect all the hype is part of the same old song & dance to get people to load up big before a R/S. Not bashing. Just the facts.
IP: Logged |
posted
SMMW is rising from the dead. There could be great potentials here. ---------------------------------------
Summus Works, Inc. Announces Business Operations to Target Diabetes Care Marketplace Thursday August 16, 8:05 am ET
SUN VALLEY, Calif., Aug. 16, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Other OTC:SMMW.PK - News), due to its recent acquisition of BioPharmetics assets and business operations, announced today the company's plan of operations.
The company released the following statement: ``As BioPharmetics, Inc. has increasingly worked on offering solutions to the healthcare arena, it is important to continue on this path for the benefit of the company and its shareholders. We intend to focus considerable interest in offering solutions for diabetic care. A recent study by the National Changing Diabetes Program, states that 12% of total federal healthcare was spent on Diabetes. That translates into a $645 billion marketplace here in the U.S. alone,'' stated Mr. Dan Burgess, CEO of Summus. ``The solutions the company offers are cutting-edge, appeal to managed care companies, and give the physician or healthcare coordinator, information to deliver the highest quality of patient care possible in today's healthcare environment.''
About Summus Works, Inc.
Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. Through this acquisition, the company will have the ability to market and sell a myriad of healthcare, anti-aging, and cosmeceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.
This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Contact: Summus Works, Inc. Dan Burgess (888) 607-9495 summus*summusworks.com
-------------------------------------------------------------------------------- Source: Summus Works, Inc.
IP: Logged |
posted
If I here "get on board the train is ready to take off" then i am jumping off my building.I think we all hope this will go up just a little (wishful thinking)but IMHO if this ever does hit .0002 i think there will be a mass exodus to the door.
IP: Logged |
posted
omg "to da Moon" i have been in these stocks for many years and only seen to da moon once and that was when i bought taser guns stock for dirt cheap and was able to take a couple of years off after selling.I am always hoping for the diamond in the ruff but times have changed.
IP: Logged |
posted
Well "To da moon" sounds good. But really, if they can just get 1% of that $645B market, that would be $6.4B a year. Wow! I see SMMW then trading at $20 or $30 a share.
IP: Logged |
posted
>> I see SMMW trading at $20 to $30 a share <<
I guess the boys in the boiler room really are working overtime these days...lol At least we're finding who they are. Will the real paid pumpers please stand up!...lol
IP: Logged |
posted
Hey, I'm definitely not a paid pumper and not even a self pumper. I'm just using logic here. It is possible to get a small share of the Diabetes healthcare market if they are serious this time around. Even just .01% (one hundredth of 1%) would be $64.8M which they could probably do. That would send the stock to at least $1.00, assuming they buyback a few billion.
IP: Logged |
posted
Two words -- FOREX and COMMODITIES! I'm doing ever better in both than in this market No MM manipulation in either. I still hold onto scores of micro-cap shells in hopes of another LFZA (I cashed in BIG on that). I bought a ton of .999 silver bullion and some gold with, put the rest into the FOREX, and took some much deserved time off. Forget this POS. It ain't goin nowhere.
IP: Logged |
posted
Agreed. Far to many O/S and more being added to the pot. The one thing, and the ONLY thing, this turd has going for it is that it's a fairly clean shell it's taxes are paid up, and it is generating some revenue at least. An unusuall combination for most shells. That said, such would make this good candidate for a R/M if a private company wanted to go public thru this turkey. However, I don't think Dan will sell this out being as hard headed as he is. This is his "baby" and he wants to make it into something special. If it ever does R/M, however, this could be the next LFZA. Keeps you wondering doesn't it?....
IP: Logged |
posted
Summus Works, Inc. Announces Paul Lisenby and Ben Friedman Appointed to Board of Directors Wednesday August 22, 1:47 pm ET
SUN VALLEY, Calif., Aug. 22, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Other OTC:SMMW.PK - News) announced that due to its recent acquisition of BioPharmetics assets and business operations, Paul D. Lisenby and Ben Friedman of BioPharmetics have been appointed to Summus' Board of Directors. About Summus Works, Inc.
Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. Through this acquisition the company will have the ability to market and sell a myriad of healthcare, anti-aging, and cosmeceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.
posted
Out with the old, in with the new. Dan is no longer CEO, that could be a good sign. --------------------------------
Summus Works, Inc. Announces Paul Lisenby and Ben Friedman Appointed Officers Tuesday September 4, 8:30 am ET
SUN VALLEY, Calif., Sept. 4, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Other OTC:SMMW.PK - News) announced the company has appointed Mr. Paul D. Lisenby as Chairman and CEO, and Mr. Ben Friedman President of the Company. Additionally, Dan Burgess and Ian Lamphere have resigned from the Board of Directors of the Company effective immediately. About Summus Works, Inc.
Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. The company distributes healthcare, anti-aging, and cosmiceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.
posted
BioPharmetics (BPMT) Announces Dividend Payout to Shareholders for Recent Asset Sale to Summus Works, Inc. Thursday August 23, 6:31 am ET
Company Looks to Target New Acquisition to Grow Shareholder Value
SUN VALLEY, CA--(MARKET WIRE)--Aug 23, 2007 -- BioPharmetics, Inc. (Other OTC:BPMT.PK - News) announced today that on or about September 13, 2007, the Company will announce the record date and structured dividend payout of shares of Summus Works, Inc. to BioPharmetics, Inc. shareholders resultant of the recent sale of assets to BioPharmetics, Inc. Management stated that while the exact details of the dividend are currently being structured, it will be paid pro rata to BioPharmetics shareholders. ADVERTISEMENT
In other news, the company is actively targeting new acquisitions for the company and expects to announce pertinent material developments to that end before Labor Day weekend. Ideal acquisition targets have been identified and due diligence is underway, management concluded.
IP: Logged |
posted
BioPharmetics (BPMT) Announces Closing of Acquisition of Azteq USA, Inc. and OC Solar Power Tuesday September 4, 8:30 am ET
SUN VALLEY, CA--(MARKET WIRE)--Sep 4, 2007 -- BioPharmetics, Inc. (Other OTC:BPMT.PK - News) announced today the Company finalized the acquisition of Azteq USA, Inc., including OC Solar Power technologies.
Azteq USA, Inc. is a Wyoming corporation and proprietor of OC Solar Power technology, and the Azteq family of motorsports divisions Azteq Motorsports Racing, and Azteq Design.
OC Solar Power is a licensed partner of Champ Car as well as Robby Gordon Motorsports and Dale Jarrett Racing Adventure (both of NASCAR fame). OC Solar Power designs and manufactures apparels, accessories and hard goods with integrated patented solar power technologies for charging low voltage devices including Apple iPods™ and other MP3 players, cell phones, laptop computers, gaming consoles and more.
The company issued the following statement, "After conducting our proper due diligence, we feel this is a strong company to bring into BioPharmetics, Inc. and we have finalized the acquisition. The company will announce further developments regarding this acquisition in the very near future."
I told you I bought it years ago . I was a baby investor then . I was barely crawling away from the egg shell I cracked out of when one of you talked me into it . I never sold and now knews in coming . Got a problem with that . They have never done a reverse split since I bought and that is AWESOME .
IP: Logged |
I was a baby investor then . I was barely crawling away from the egg shell I cracked out of when one of you talked me into it .
If someone talked you into this I can pretty much guarantee that it wasn't me. The only thing I can think of is, you were probably off on one of your rants,....possibly praising PAIM or somethin, and as a JOKE, someone told you that if you liked that one, you'd like this as well.
AND, as far as your being a 'baby investor then', that pretty much hasn't changed.
-------------------- ~You aren't wealthy until you have something money can't buy.~
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Razz]](tongue.gif)
Dan Did It...I'll Be Damned......
![[Big Grin]](biggrin.gif)
Second PR Today, states all, and this one is CRYSTAL CLEAR....no questions to be asked.... 
